Analyst firms · Raymond James · JNCE
Raymond James JNCE price target and rating history
Jounce Therapeutics Inc. (JNCE) · Health Care
Raymond James rates Jounce Therapeutics Inc. (JNCE) Strong Buy with a $20 price target, as of its latest action on May 6, 2022. It has published 3 rating actions on JNCE since September 2021, including 2 upgrades and 0 downgrades.
- Current rating
- Strong Buy
- Price target
- $20
- Median target, all firms
- Too few
- Actions on JNCE
- 3
Raymond James price target on JNCE
Every Raymond James rating on JNCE
- May 6, 2022
- Nov 5, 2021
- Sep 14, 2021
Questions about Raymond James and JNCE
- What is Raymond James's price target for JNCE?
- Raymond James's latest stated price target for Jounce Therapeutics Inc. (JNCE) is $20, from its action on May 6, 2022.
- What is Raymond James's rating on JNCE?
- Raymond James rates JNCE Strong Buy, a bullish rating, as of May 6, 2022.
- When did Raymond James last change its view on JNCE?
- On May 6, 2022, Raymond James upgrades to Strong Buy from Outperform, price target $15 to $20.
All Raymond James ratingsJNCE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.